Lung adenocarcinoma (LUAD) is a major lung cancer subtype characterized here as an immune-cold tumor with spatial immune exclusion, and the banf1 axis was highlighted as a prognostic tumor-intrinsic program associated with an unfavorable immune landscape. It has been studied across multiple therapeutic contexts, including resistance to third-generation EGFR-TKIs, PD-L1 blockade, STING agonist response monitoring, and combined radiotherapy plus lenvatinib. Recent work also identified l3emp as a microprotein that promotes LUAD progression by catalyzing SIRT1 deubiquitination, linking post-translational regulation to tumor growth. Multi-omics and machine-learning studies have further implicated PANoptosis core genes and tumor microenvironment mechanisms in LUAD biology, while spatial transcriptomics has helped define immune-exclusion programs relevant to immunotherapy response. A patient-relevant orthotopic model and liquid-biopsy-guided sequential targeted therapy studies underscore the translational focus of current LUAD research. Overall, these findings position LUAD as a disease where immune evasion, targeted-therapy resistance, and biomarker-driven treatment selection are central themes.
Immune microenvironment and immunotherapy
- Integrated spatial transcriptomics and pan-cancer XGBoost modeling identified LUAD as an immune-cold cancer with spatial immune exclusion, supporting immunotherapy-response prediction (PMID:41925746).
- banf1 was significantly upregulated in LUAD tissues and linked to a complex immune landscape and poor overall survival, suggesting a tumor-intrinsic prognostic role (PMID:42000935).
- ICOS-targeted peptide imaging was used to monitor response to STING agonist therapy in LUAD mouse models, providing a noninvasive readout of immune activation (PMID:41991338).
- Lenvatinib was studied as a potentiator of radiotherapy + PD-L1 blockade, indicating interest in combination strategies to overcome immune resistance (PMID:41481002).
Targeted therapy resistance and biomarker discovery
- LUAD was used as the disease context for biomarker exploration after resistance to third-generation EGFR-TKIs, with implications for immunotherapy plus chemotherapy selection (PMID:41981503).
- Liquid biopsy-based detection of acquired MET resistance enabled sequential targeted therapy in MET fusion-positive NSCLC, relevant to LUAD-like oncogene-driven disease management (PMID:42015375).
- The orthotopic pre-clinical system and patient-relevant immune profiling study provided a translational model for evaluating LUAD biology and treatment response (PMID:42026061).
Tumor progression and cell-death mechanisms
- l3emp was reported to trigger LUAD progression by catalyzing SIRT1 deubiquitination, identifying a novel oncogenic mechanism (PMID:41942609).
- Multi-omics and machine-learning analysis identified PANoptosis core genes in LUAD and linked them to tumor microenvironment mechanisms and therapeutic potential (PMID:41935997).
- BANF1 was also described as a prognostic biomarker associated with tumor-intrinsic programs, reinforcing its relevance to LUAD progression biology (PMID:42000935).